3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Colorectal Neoplasms
9
Stomach Neoplasms
6
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Solid Tumor
3
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Muscle Invasive Bladder Cancer
1
Interventions
Dexamethasone
33
Cyclophosphamide
29
venetoclax
18
fludarabine
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
tislelizumab
×
Clear all
NCT07502768
2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2
Not yet recruiting
107 enrolled